<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00296699</url>
  </required_header>
  <id_info>
    <org_study_id>IRB4943</org_study_id>
    <nct_id>NCT00296699</nct_id>
  </id_info>
  <brief_title>A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression</brief_title>
  <official_title>A Pilot Study Assessing Duloxetine's Efficacy in Atypical Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <brief_summary>
    <textblock>
      This is a Pilot Study to get a first indication whether Duloxetine may be effective for
      depressed patients with Atypical Features.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This Open Pilot Study will assess whether Duloxetine is effective for patients with Atypical
      Features. 20 patients having Major Depressive Disorder with Atypical Features or Dysthymic
      Disorder will receive Duloxetine in open fashion for 8 weeks. Dose will begin with 20 mg/d
      and increase to PDR maximal dose of 120 mg/d, if tolerated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Depression Scale (HAM-D)</measure>
    <time_frame>10 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atypical Depression Diagnostic Scale (ADDS)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Beck Depression Inventory (BDI)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression (CGI)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression (PGI)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inventory of Depressive Symptoms(IDS)</measure>
    <time_frame>10 weeks</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Atypical Depression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Day 1-7: 20 mg/d; day 8-24: 30 mg/d; day 15-28: 60 mg/d; day 29-56: 120 mg/d.
* dose raises will occur only if pt. is tolerating the previous dose and not remitting.; dose may be lowered or increased in 30 mg increments if pt. has difficulty tolerating.</description>
    <other_name>Cymbalta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  DSM-IV Major Depression or Dysthymia with Atypical Features

          -  Age 18-65

          -  Physically healthy

          -  HAMD(24) &gt; 14

        Exclusion Criteria:

          -  Prior experience with Duloxetine

          -  History of Psychosis or Bipolar Disorder, Borderline Personality Disorder

          -  Unstable medical disorder; any history of Epilepsy

          -  Currently taking medication that can interact with Duloxetine

          -  Current (past six months) Substance Use Disorder (illicit drugs and/or alcohol)

          -  Serious suicidal ideation judged at least somewhat likely to be acted upon or require
             hospitalization

          -  Current (past two weeks) use of psychoactive medication (four weeks for Fluoxetine)

          -  Pregnancy

          -  Currently breast feeding

          -  Fecund women failing to use acceptable birth control

          -  Refractory Depression (defined as failure to respond to one or more adequate trials of
             marketed antidepressants [i.e., &gt;=2/3 PDR maximum dose for at least 4 weeks] during
             current episode)

          -  Serious suicidal ideation, recent (past six months) suicidal activity, any life-time
             history of serious suicide attempt (e.g., admitted to ICU, any duration of coma)

          -  Currently taking medication deemed effective
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan W. Stewart, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute - Columbia University Department of Psychiatry</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Depression Evaluation Service - New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.depression-nyc.org</url>
    <description>Depression Evaluation Service - official website</description>
  </link>
  <link>
    <url>http://www.nyspi.org</url>
    <description>New York State Psychiatric Institute - official website</description>
  </link>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2006</study_first_submitted>
  <study_first_submitted_qc>February 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2006</study_first_posted>
  <last_update_submitted>January 14, 2008</last_update_submitted>
  <last_update_submitted_qc>January 14, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 15, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jonathon W. Stewart</name_title>
    <organization>New York State Psychiatric Institute</organization>
  </responsible_party>
  <keyword>Atypical Depression</keyword>
  <keyword>Major Depressive Disorder</keyword>
  <keyword>Dysthymic Disorder</keyword>
  <keyword>Atypical Features</keyword>
  <keyword>Duloxetine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

